GlassScriptPhysician profile
Melissa M Parrish
NPI 1275955379
$11,389.48
in general payments reported to CMS, 2019-2025
28 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,952 · 2022: $2,450 · 2023: $2,765 · 2024: $2,706 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,888 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,887.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,320.18 | 2021-2025 | |
| Amgen INC. | $1,882.50 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,277.74 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $1,006.23 | 2021-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $683.01 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $615.35 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $584.31 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $325.93 | 2021-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $237.05 | 2021-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $188.24 | 2021-2024 | Lupkynis |
| Sobi, INC | $172.73 | 2022-2024 | |
| Pfizer INC. | $172.59 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.87 | 2023-2025 | Cyltezo, Ofev |
| Astrazeneca Pharmaceuticals LP | $98.94 | 2022-2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $96.49 | 2023-2024 | Idacio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $83.96 | 2021-2023 | Krystexxa |
| Sandoz INC. | $83.23 | 2024-2025 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $65.02 | 2021-2023 | Uptravi |
| Genzyme Corporation | $63.04 | 2021-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $50.46 | 2024 | Arcalyst |
| Genentech USA, INC. | $49.29 | 2021-2025 | Actemra |
| Kiniksa Pharmaceuticals, LTD. | $45.52 | 2023 | Arcalyst |
| Janssen Scientific Affairs, LLC | $35.49 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $30.72 | 2022-2025 | Strensiq |
| Tersera Therapeutics LLC | $20.94 | 2025 | Quzyttir |
| Mylan Institutional INC. | $18.03 | 2023 | Hulio |
| Kyowa Kirin, INC. | $13.65 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.